Brolucizumab
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Brolucizumab
- Pharmacist Assessment Report
- Brolucizumab: anti-VEGF-A single-chain antibody fragment → mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Brolucizumab: anti-VEGF-A single-chain antibody fragment → mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies
One-Sentence Summary
Brolucizumab is an anti-VEGF-A single-chain antibody fragment (scFv) given by intravitreal injection and marketed in Australia as Beovu. The TxGNN model predicts it may be relevant to mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies, but there are 0 clinical trials and 0 publications supporting this direction in the data compiled for this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies |
| TxGNN Prediction Score | 0.9967 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge of the drug class, brolucizumab is an anti-VEGF-A single-chain antibody fragment that blocks VEGF-A signalling and so reduces abnormal blood vessel growth and vascular leakage.
No direct mechanistic link to oxidative phosphorylation disorders caused by nuclear DNA anomalies has been established. VEGF signalling may play a peripheral role in the tissue hypoxia and angiogenic responses seen in some mitochondrial diseases, but this is speculative. The high TxGNN score is a model-based prediction only. No trial or publication in the data compiled for this report supports it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 12667Q | Beovu | Solution for intravitreal injection 19.8 mg in 0.165 mL pre-filled syringe | Not recorded in the local data |
The data show one valid single-ingredient licence, supplied as an injectable (intravitreal) product.
Safety Considerations
No label-based warnings, contraindications or drug interaction data are available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Note on the intravitreal route: the intravitreal formulation is designed for ocular use. Its suitability for any systemic or non-ocular indication has not been assessed (route compatibility is pending).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (evidence level L5). There are no clinical trials or publications for this disease, and no mechanistic link has been established. The route compatibility of an intravitreal product with this indication is also unassessed.
To proceed, the following is needed:
- Mechanism of action data for brolucizumab, and a plausible mechanistic link to nuclear-DNA-driven oxidative phosphorylation disorders
- Preclinical or clinical studies that directly address this disease
- Assessment of route compatibility and a feasible delivery approach
- Warnings, contraindications and interaction data from the TGA-approved Product Information, to allow safety screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.